Mass. Mover

Dyax slumps as trial is ended


Burlington-based Dyax Corp. plunged the most in 11 months after it ended a trial of its leading drug candidate for swelling of the skin caused by blood pressure medicines. The trial was halted because the drug, known as ecallantide, may not be effective, according to a statement from the company. Safety wasn’t a reason for the decision, Dyax said. Dyax said it is assessing options regarding future trials to treat angioedema caused by blood pressure medicines.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of